Evinacumab for Homozygous Familial Hypercholesterolemia

J. Raal, Frederick; S. Rosenson, Robert; F. Reeskamp, Laurens; Kees Hovingh, G.; J.P. Kastelein, John; Rubba, Paolo; Ali, Shazia; Banerjee, Poulabi; Chan, Kuo‐Chen; A. Gipe, Daniel; Khilla, Nagwa; Pordy, Robert; M. Weinreich, David; D. Yancopoulos, George; Zhang, Yi; Gaudet, Daniel

doi:10.1056/nejmoa2004215

Public

Evinacumab for Homozygous Familial Hypercholesterolemia

Published in New England Journal of Medicine • Aug 20, 2020

Authors:

Frederick J. Raal

Robert S. Rosenson

Laurens F. Reeskamp

Abstract

BACKGROUND: ) are associated with hypolipidemia and protection against atherosclerotic cardiovascular disease. Evinacumab, a monoclonal antibody against ANGPTL3, has shown potential benefit in patients with homozygous familial hypercholesterolemia. METHODS: In this double-blind, placebo-controlled, ...

Subject

Familial hypercholesterolemia

Internal medicine

Null allele

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!